<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?</h1>
  <ul>
<li>AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, up 4.2% year over year, as higher sales of Venclexta and contributions from new drugs, Elahere and Epkinly, more than offse</li>
<li>Stelara sales declined 38.6% in the first half of 2025.</li>
<li>It expects the Innovative Medicine business to grow 5% to 7% from 2025 to 2030.</li>
<li>The Zacks Consensus Estimate for J&amp;J’s 2025 sales and EPS implies a year-over-year increase of 5.2% and 8.8%, respectively.</li>
<li>Sales of its neuroscience drugs increased 20.3% to almost $5 billion in the first half of 2025, driven by higher sales of Botox Therapeutic, depression drug Vraylar and newer migraine drugs Ubrelvy and Qulipta.</li>
<li>Skyrizi and Rinvoq generated combined sales of $11.6 billion in the first half of 2025.</li>
<li>JNJ Estimate Movement Image Source: Zacks Investment Research The Zacks Consensus Estimate for AbbVie’s 2025 sales and EPS implies a year-over-year increase of 7.5% and 18.9%, respectively.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/j-j-vs-abbvie-healthcare-131500100.html">Source</a> · 2025-09-08T13:15:00+00:00</p>
</body>
</html>